Zebrafish

Consolidating key protocols and approaches to help researchers navigate the important and evolving field of zebrafish models for toxicity screening, this new title describes the methods for using the zebrafish as a model organism to assess compound-induced toxicity on all major organs.  Individual chapters that concentrate on assays for each organ system are included and various analytical tools including microscopy, microplate readers, high content imaging systems, ECG, blood pressure monitors, high speed video and motion detectors are described.

Patricia McGrath, MBA, is President and CEO of Phylonix Pharmaceuticals, Inc. She has some twenty-five years of experience in high-tech and biotechnology management. Phylonix Pharmaceuticals develops and markets novel in vivo zebrafish-based assays for therapeutic and industrial screening for cancers, central nervous system and cardiovascular diseases, apoptosis, and toxicity.